<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343021">
  <stage>Registered</stage>
  <submitdate>10/06/2011</submitdate>
  <approvaldate>23/06/2011</approvaldate>
  <actrnumber>ACTRN12611000647932</actrnumber>
  <trial_identification>
    <studytitle>Administration of pantoprazole and its effects  on gastric PH,inflammatory &amp; anti inflammatory factors in critically ill patients.</studytitle>
    <scientifictitle>A Comparative study of bolus &amp; Continuous administration of pantoprazole on gastric PH and its effect on inflammatory &amp; anti inflammatory cytokines(IL1,TNFa vs IL10,EGF) in      critically ill patients.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastric acidity</healthcondition>
    <healthcondition>Inflamatory &amp; Anti inflamatory cytokines in gastric juice and blood</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: Critically ill patients with gastric pH below 3,bolus Pantoprazole(80 mg/day,48 hours)
Arm 2:Critically ill patients with gastric pH below 3, continuous infusion  Pantoprazole(80mg/day,48 hours)
Arm3:Critically ill patients with gastric pH below 3,continuous
infusion Ranitidin(150mg/day,48hours)
pH measure by a pH meter probe and litmus paper</interventions>
    <comparator>Critically ill patients with gastric pH below 3,continuous
infusion Ranitidin(150mg/day,48hours)</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in inflamatory &amp; anti inflamatory cytokines(IL1,TNFa vs IL10,EGF) in gastric juice, ELISA IMMUNOASSAY</outcome>
      <timepoint>0,12,24&amp;48 hours after starting Administration of pantprazole or Ranitidine</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in inflamatory anti inflamatory cytokines(IL1,TNFa vs IL10,EGF) in  plasma,ELISA IMMUNOASSAY</outcome>
      <timepoint>0,12,24&amp;48 hours after starting Administration of pantprazole or Ranitidine</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria :
1-Age&gt;18
2-Clinical need for a nasogastric tube
3-Expectation of 48 hrs of nothing by mouth status 
4-Baseline gastric pH &lt;3.5
5-High risk patients for stress ulcer(one of these risk 
   factors)
 patients with Coagulopathy disorders.
 Ventilator dependant patients, shock, Respiratory       failure,  trauma</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1-History of peptic ulcer disease 
2-Patients with zollinger Ellison
3-Recipients of H2 blockers &amp; NSAIDS
4-Tube feeding 
5-Creatinine&gt;2 or Creatinine &gt; %25 increase in base line 
6-Abnormal LFT (3 times&gt;base line) 
7- Renal failure</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>10/11/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tehran university of medical sciences</primarysponsorname>
    <primarysponsoraddress>16 AZAR AVE,Tehran university of medical sciences,Faculty of pharmacy,Tehran 1417614411</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Tehran university of medical sciences</fundingname>
      <fundingaddress>16 AZAR AVE,Tehran university of medical sciences,faculty of pharmacy, Tehran 1417614411</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Cytokines have some roles in stress related mucosal damage (SRMD),some studies mentioned probable anti inflamatory effects of proton pump inhibitors(PPIs).
The primary purpose of this study is to find  that if PPIs in critically ill patients can reduce inflamatory factors secreted in gastric juice in addition to increase the gastric pH?</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Pharmaceutical Sciences Research centre</ethicname>
      <ethicaddress>16 AZAR AVE,, Faculty of Pharmacy,Pharmaceutical Sciences Research Center, Tehran 1417614411.</ethicaddress>
      <ethicapprovaldate />
      <hrec>86-4-13:7</hrec>
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mojtahedzade,Mojtaba</name>
      <address>16 AZAR AVE,Tehran university of medical sciences,faculty of pharmacy,Department of clinical pharmacy,Tehran
1417614411</address>
      <phone>+98 912 1056032</phone>
      <fax />
      <email>Mojtahed@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mojtahedzade,Mojtaba</name>
      <address>16 AZAR AVE,Tehran university of medical sciences,faculty of pharmacy,Department of clinical pharmacy,Tehran 1417614411</address>
      <phone>+98 912 1056032</phone>
      <fax>+982166954709</fax>
      <email>Mojtahed@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>